Autolus Therapeutics’ Post

At the upcoming American Society of Hematology Annual Conference, results from multiple clinical and preclinical studies on four of our investigational drug candidates (olverembatinib, lisaftoclax, APG-2449, and APG-5918) will be presented. The presentations include data in Chronic Leukemias (CML and CLL/SLL), Acute Leukemias (AML, ALL, and MDS), as well as lymphomas. https://lnkd.in/ertKNcpD #ASH #cancerresearch #drugdevelopment #leukemia #lymphoma #myeloma

Peripheral T Cell Lymphomas Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Celleron Therapeutics, Myeloid Therapeutics, Astex Pharma: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Peripheral T Cell Lymphomas pipeline constitutes 40+ key companies continuously working towards developing 40+ Peripheral T Cell Lymphomas treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Preliminary clinical data from CT0590, an allogeneic BCMA CAR-T leveraging our THANKuCAR platform, demonstrates significant potential in addressing the inadequate efficacy of existing allogeneic CAR-Ts. THANKuCAR platform is specifically designed to mitigate the challenges of HvGR and improve the durability of response in allogeneic CAR-T therapies. In the IIT trial, two subjects achieved stringent complete response (sCR). One subject with RRMM has maintained an ongoing sCR with a duration of response (DOR) exceeding 23 months. The second subject, with primary plasma cell leukemia (pPCL), exhibited a DOR of 20 months. Both patients demonstrated CAR copy numbers peaking at over 280,000 copies/µg of genomic DNA. Building upon the THANKuCAR platform, THANKuCAR Plus is developed to offer enhanced anti-tumor efficacy across broader patient populations. My colleague Nishan Rajakumaraswamy, Raffaele Baffa, and I will be at ASH for the data presentation. If you're interested in connecting, feel free to reach out for a coffee chat.

Advanced Renal Cell Carcinoma Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Molecure S.A., Daiichi Sankyo, Janux Therapeutics: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Advanced Renal Cell Carcinoma pipeline constitutes 50+ key companies continuously working towards developing 60+ Advanced Renal Cell Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Adaptimmune Therapeutics on Wednesday revealed primary findings from a pivotal Phase II study demonstrating that its investigational TCR T cell therapy lete-cel elicited high rates of treatment response in patients with advanced or metastatic synovial sarcoma or myxoid/round cell liposarcoma. The results of the IGNYTE-ESO study, to be presented during the 2024 Annual Meeting of the Connective Tissue Oncology Society in San Diego, showed that of the 64 treated patients, 42% responded to lete-cel, including six who achieved complete response and 21 who reached partial response. Median duration of response was 12.2 months overall, 18.3 months in synovial sarcoma and 12.2 months in myxoid/round cell liposarcoma (MRCLS). With these pivotal findings, Adaptimmune will initiate a rolling Biologics License Application by the end of 2025, seeking approval for lete-cel in synovial sarcoma or MRCLS. #biotech #biopharma #pharma

Nektar Therapeutics announced promising results from a Phase 2 study of its experimental drug #NKTR255, which improved six-month complete response rates in relapsed large B-cell #lymphoma from 50% to 73%. It enhanced #CARTcell expansion and durability, prompting some stable or partial responses to become complete responses. These early findings suggest NKTR-255 could help achieve more sustained remission in hard-to-treat #cancers. By Tracy Mokwe https://lnkd.in/dn3xdmjB

Cutaneous T-Cell Lymphoma Pipeline Drugs Analysis Report, 2024: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Micreos, Scopus BioPharma, MediSix Therapeutics, Jiangsu Simcere: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Cutaneous T-Cell Lymphoma pipeline constitutes 30+ key companies continuously working towards developing 35+ Cutaneous T-Cell Lymphoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

ABL Bio, a company specializing in dual antibodies, announced on December 4 that its partner, CStone Pharmaceuticals (hereinafter referred to as CStone), will present the latest clinical data on 'CS5001 (ABL202·LCB71),' a ROR1 (Receptor tyrosine kinase-like orphan receptor 1) antibody-drug conjugate (ADC) candidate, in a poster session at the 66th American Society of Hematology (ASH) Annual Meeting. https://lnkd.in/gw5Y2Bue

Asieris Pharmaceuticals (SHSE: 688176) announced that the US FDA has approved the Investigational New Drug (IND) application for APL-2302, a ubiquitin-specific protease 1 (USP1) inhibitor, for the treatment of advanced solid tumors. APL-2302 is a novel USP1 inhibitor with fully independent intellectual property rights, functioning via a "synthetic lethality" mechanism. Non-clinical pharmacodynamics (PD) studies show that APL-2302 is an active USP1 inhibitor, demonstrating excellent tumor suppression efficacy in vitro and in vivo, both as a monotherapy and in combination therapies. It offers promising potential as a new treatment option for patients with advanced solid tumors, including those with breast, ovarian, prostate, and other solid tumors characterized by specific biomarkers, such as BRCA mutations. #FDAApproval #INDApplication #APL2302 #USP1Inhibitor #CancerResearch #SolidTumors #SyntheticLethality #CancerInnovation #PharmaNews #Oncology #QimingPortfolio #QimingHealthcare Read More: https://lnkd.in/gpk-nmW9

Poseida Therapeutics, Inc. has showcased the exceptional capabilities of its proprietary non-viral technology platform, successfully developing allogeneic, TSCM-rich CAR-T therapies. These advancements hold promise for enhancing clinical outcomes and broadening access to vital treatments. The interim clinical data for P-BCMA-ALLO1 in multiple myeloma patients underscores this potential. Poseida and its dedicated team are set to join Roche's Pharmaceuticals Division, aiming to further the fight against cancer. The transaction is anticipated to conclude in the first quarter of 2025, subject to closing conditions. #BorderlessNewsletter #Borderless #CellTherapy #HealthcareInnovation